Clinical Trials

Familial amyloid polyneuropathies (FAPs)

Displaying 2 studies

To Evaluate The Long-term Safety And Tolerability Of Acoramidis In Participants With Newly Diagnosed ATTR-CM (ACT-EARLY OLE) Jacksonville, FL

The AG10-504 study is an open-label extension study of acoramidis in participants with newly diagnosed transthyretin amyloid cardiomyopathy (ATTR-CM) or both ATTR-CM and transthyretin amyloid polyneuropathy (ATTR-PN).
A Study To Evaluate The Efficacy And Safety Of AKCEA-TTR-LRx In Participants With Hereditary Transthyretin-Mediated Amyloid Polyneuropathy Scottsdale/Phoenix, AZ

The purpose of this study is to evaluate the effectiveness and safety of AKCEA-TTR-LRx after administration for 65 weeks to patients with hereditary transthyretin-mediated amyloid polyneuropathy (hATTR-PN), as compared to the NEURO-TTR trial (NCT01737398).

For more information, please visit http://www.neuro-ttransform.com/.